Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andrew McConaghie

Senior Writer

Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.

He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.

Set Alert for Articles By Andrew McConaghie

Latest From Andrew McConaghie

Surprise As FDA Approves Sarepta’s Duchenne Drug Vyondys 53

The FDA has overcome doubts about the drug's safety and reversed its decision in just four months.
Approvals BioPharmaceutical

Seven Talking Points At ASH 2019

The tireless pace of change in hemato-oncology was showcased in Orlando.

ImmunoOncology Cancer

J&J’s Darzalex Scores Again In Frontline Myeloma

Janssen’s hemato-oncology success rolls on with impressive new overall survival data

Research & Development Blood & Coagulation Disorders

As Bluebird’s CAR-T Competition Intensifies, Sickle Cell Therapy Brings Upside

While the BCMA-targeting CAR-T competition is grabbing attention, bluebird has good news in sickle cell therapy.

UniQure Aiming To Be First With Hemophilia B Gene Therapy

The company has come a long way since gene therapy flop Glybera, and claims best-in-class status for viral vector.

Research & Development Blood & Coagulation Disorders

Astellas To Pay $3bn For Gene Therapy Company Audentes

Japanese company joins the ranks of big pharma buying up gene therapy pioneers

Asia Pacific Gene Therapy
See All
UsernamePublicRestriction

Register